Pharmacotherapy Case Studies: Pregnancy, STIs, and Pediatrics
This paper presents four pharmacotherapy case studies addressing common clinical scenarios encountered in primary care. The cases cover: management of hypertension in a 32-week pregnant patient using labetalol after ACE inhibitor discontinuation; dual antibiotic treatment of gonorrhea and chlamydia with ceftriaxone and doxycycline; topical erythromycin therapy for bacterial conjunctivitis in a sulfa- and penicillin-allergic child; and weight-based amoxicillin dosing for acute otitis media in a toddler with a contingency plan using cefdinir if allergy develops. Each scenario includes medication orders, monitoring plans, and patient education recommendations grounded in current clinical guidelines.
- Hypertension in Pregnancy: Labetalol Management: Labetalol selection and monitoring for pregnant hypertensive patient
- Gonorrhea and Chlamydia: Dual Antibiotic Therapy: Ceftriaxone and doxycycline orders for co-infection treatment
- Bacterial Conjunctivitis in a Pediatric Patient: Erythromycin ophthalmic treatment for allergy-limited child
- Acute Otitis Media: Dosing and Allergy Considerations: Weight-based amoxicillin dosing with cefdinir backup plan
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each case follows a consistent SOAP-style framework — problem, background, medication order, monitoring, and patient education — making clinical reasoning transparent and easy to follow.
- Drug selection is explicitly justified by contraindications, allergy profiles, and current guideline recommendations, demonstrating evidence-based prescribing rather than rote memorization.
- Dosage calculations are shown step-by-step (e.g., weight-based amoxicillin for the 15 kg toddler), providing a model for safe pediatric prescribing practice.
Key academic technique demonstrated
The paper demonstrates clinical decision-making by linking patient-specific variables (gestational age, allergy history, weight) directly to pharmacological choices. Rather than listing medications generically, the author rules out contraindicated agents and ranks alternatives by safety and efficacy — a hallmark of applied pharmacotherapy reasoning at the graduate level.
Structure breakdown
The paper is organized as four parallel case studies. Each case opens with a problem statement and relevant background, moves into a structured medication order with rationale, then closes with monitoring parameters and patient education. This modular structure allows each scenario to stand alone while the cumulative paper demonstrates breadth across obstetric, infectious disease, and pediatric pharmacotherapy domains.
Hypertension in Pregnancy: Labetalol Management
Problem: A 32-year-old pregnant female at 24 weeks gestation presents with a history of hypertension previously treated with lisinopril, which was discontinued due to pregnancy. Her current blood pressure of 150/95 mmHg indicates uncontrolled hypertension.
Background: Hypertension in pregnancy is a significant risk factor for maternal and fetal complications, including preeclampsia, preterm birth, and fetal growth restriction (Agrawal & Wenger, 2020). ACE inhibitors such as lisinopril are contraindicated in pregnancy due to their teratogenic effects, requiring alternative treatment.
Treatment Goals: The goal is to reduce the patient's blood pressure to below 140/90 mmHg, minimizing the risk of complications while maintaining safety for both the mother and the fetus (Garovic et al., 2022). Medications that are safe in pregnancy must be selected.
Medication Options: First-line antihypertensive drugs during pregnancy include methyldopa, labetalol, and nifedipine (Conti-Ramsden et al., 2024).
Methyldopa acts centrally by inhibiting sympathetic outflow, thereby reducing blood pressure. It is safe in pregnancy but may cause sedation, which can affect patient adherence.
Labetalol is a combined alpha- and beta-blocker that reduces blood pressure without significantly affecting uteroplacental blood flow.
Nifedipine (extended-release) is a calcium channel blocker that can also be used, especially in cases of severe hypertension.
Given the patient's elevated blood pressure, labetalol is preferred for its efficacy and safety profile.
Medication Order:
Drug: Labetalol 100 mg | Dose: 100 mg | Route: Oral | Frequency: Twice daily (BID) | Special instructions: Titrate dose upward every 1–2 weeks as needed to achieve target blood pressure | Quantity dispensed: 30-day supply | Refills: 1
Monitoring:
Weekly blood pressure checks should be conducted to ensure the treatment is effective. Monthly blood work should assess kidney function (BUN, creatinine) and electrolytes, particularly potassium, as labetalol may affect renal function. Fetal monitoring via growth ultrasounds should be performed every four weeks to assess fetal development, especially if blood pressure control remains challenging.
Patient Education:
The patient should be informed about the importance of adhering to the prescribed medication and attending regular prenatal visits. She should be educated on monitoring for signs of preeclampsia — such as headaches, visual disturbances, or sudden swelling — which require immediate medical attention.
References
Agrawal, A., & Wenger, N. K. (2020). Hypertension during pregnancy. Current Hypertension Reports, 22(9), 64.
Conti-Ramsden, F., de Marvao, A., & Chappell, L. C. (2024). Pharmacotherapeutic options for the treatment of hypertension in pregnancy. Expert Opinion on Pharmacotherapy, 25(13), 1739–1758.
Garovic, V. D., Dechend, R., Easterling, T., Karumanchi, S. A., McMurtry Baird, S., Magee, L. A., Rana, S., Vermunt, J. V., & August, P. (2022). Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension, 79(2), e21–e41.
Gonorrhea and Chlamydia: Dual Antibiotic Therapy
Problem: A 24-year-old female presents with a one-week history of vaginal discharge and is diagnosed with gonorrhea. She has a sulfa drug allergy and a history of unprotected sexual activity with a new partner.
Background: Gonorrhea is a sexually transmitted infection (STI) that can lead to complications such as pelvic inflammatory disease (PID), infertility, and chronic pelvic pain if left untreated (Dombrowski, 2021). It often coexists with chlamydia, so treatment should cover both infections.
Treatment for Gonorrhea: According to CDC guidelines, the first-line treatment for gonorrhea is ceftriaxone (Barbee & St. Cyr, 2022). Since the patient has no contraindications to ceftriaxone — a sulfa allergy does not affect its use — this should be administered.
Medication Order (Gonorrhea):
Drug: Ceftriaxone 500 mg | Dose: 500 mg | Route: Intramuscular (IM) injection | Frequency: Single dose | Quantity dispensed: 1 | Refills: None
Coverage for Chlamydia: As chlamydia often co-occurs with gonorrhea, treatment with doxycycline is recommended. Doxycycline is favored over azithromycin due to its better efficacy in treating rectal chlamydia and its role in minimizing antibiotic resistance (McAnaney, 2022).
Medication Order (Chlamydia):
Drug: Doxycycline 100 mg | Dose: 100 mg | Route: Oral | Frequency: Twice daily (BID) for 7 days | Quantity dispensed: 14 tablets | Refills: None
Patient Education:
The patient should abstain from sexual activity for at least seven days after completing treatment to prevent reinfection. She should ensure her partner also receives treatment, as untreated partners can lead to reinfection. Education on safe sex practices — including the consistent use of condoms — is necessary to prevent future STIs.
Follow-Up:
The patient should return to the clinic for retesting in three months, as reinfection rates for gonorrhea and chlamydia can be high. She should be encouraged to contact the clinic if she experiences persistent symptoms, which may suggest possible treatment failure or reinfection.
References
Barbee, L. A., & St. Cyr, S. B. (2022). Management of Neisseria gonorrhoeae in the United States: Summary of evidence from the development of the 2020 gonorrhea treatment recommendations and the 2021 Centers for Disease Control and Prevention sexually transmitted infection treatment guidelines. Clinical Infectious Diseases, 74(Supplement_2), S95–S111.
Dombrowski, J. C. (2021). Chlamydia and gonorrhea. Annals of Internal Medicine, 174(10), ITC145–ITC160.
McAnaney, C. (2022). Doxycycline preferred for the treatment of chlamydia. American Family Physician, 106(5), 485.
Always verify citation format against your institution’s current style guide requirements.